Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir
| Autor: | Simona Landonio, Paola Meraviglia, Marco Bongiovanni, Teresa Bini, Elisabetta Chiesa, L. Testa, Federica Tordato, Fulvio Adorni, Patrizia Biasi, Antonio Di Biagio, Paola Cicconi, Antonella d'Arminio Monforte |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Immunology Lopinavir/ritonavir HIV Infections Hyperlipidemias Pyrimidinones Gastroenterology Lopinavir chemistry.chemical_compound Virology Internal medicine Hyperlipidemia medicine Humans Sida Ritonavir Triglyceride biology business.industry Cholesterol Hypertriglyceridemia HIV Protease Inhibitors Middle Aged medicine.disease biology.organism_classification Infectious Diseases chemistry Female business medicine.drug |
| Zdroj: | AIDS research and human retroviruses 22 (2006): 132–138. doi:10.1089/aid.2006.22.132 info:cnr-pdr/source/autori:Bongiovanni, M; Bini, T; Cicconi, P; Landonio, S; Meraviglia, P; Testa, L; Di Biagio, A; Chiesa, E; Tordato, F; Biasi, P; Adorni, F; Monforte, AD/titolo:Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir%2Fritonavir/doi:10.1089%2Faid.2006.22.132/rivista:AIDS research and human retroviruses/anno:2006/pagina_da:132/pagina_a:138/intervallo_pagine:132–138/volume:22 |
| DOI: | 10.1089/aid.2006.22.132 |
| Popis: | We studied 382 multiexperienced HIV-infected patients followed up for > or =3 months after starting lopinavir/ritonavir (LPV/r) to identify the factors predicting hypertriglyceridemia and high non-HDL cholesterol levels (triglycerides > or =200 mg/dl and/or non-HDL cholesterol > or =190 mg/dl) after 6 and 12 months of LPV/r exposure. The predictors of hypertriglyceridemia were higher baseline triglyceride levels [OR: 2.28 (95% CI: 1.67-3.12) for each additional 100 mg/dl; p = 0.001], the total duration of antiretroviral treatment [OR: 1.26 (95% CI: 1.12-1.41) for each additional year; p = 0.01], CDC stage C (OR: 2.06; 95% CI: 1.24-3.88; p = 0.02), and male gender (OR: 2.52; 95% CI: 1.42-4.74; p = 0.02); intravenous drug abusers seem less likely to develop the event (OR: 0.52; 95% CI: 0.37-0.92; p = 0.03). The predictors of high non-HDL cholesterol levels were higher baseline levels [OR: 3.92 (95% CI: 1.92-6.24) for each additional 100 mg/dl; p = 0.001) and the combination of NRTIs and NNRTIs with LPV/r (OR: 1.83; 95% CI: 1.10-3.69; p = 0.03). The 75 patients stopping LPV/r showed a significant reduction in median triglyceride and non-HDL cholesterol levels after 3 months of 39 mg/dl and 20 mg/dl (p = 0.01 for both), respectively. Patients with high triglyceride and non- HDL cholesterol levels at the start of LPV/r treatment are at higher risk of developing hyperlipidemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|